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Objective: The aim of this study is to investigate the inﬂuence of antinuclear antibodies (ANAs) on the
pregnancy and early miscarriage rates, thereby evaluating the outcome of in vitro fertilization and
intracytoplasmic sperm injection (IVF/ICSI) treatment.
Materials and methods: A total of 517 infertile female patients undergoing IVF/ICSI treatment (experi-
mental group) were chosen for this study, and 186 women with normal reproductive history (control
group) were designated as the control. Serum ANAs from the participants were tested using indirect
immunoﬂuorescence assay, while antiextractable nuclear antigens were tested by immune blot assay.
Results: The ANA expression in the infertile patients (39.45%) was higher than that in the control group
(16.13%). A high ANA titer (1:320) was found only in infertile patients. ANA positivity signiﬁcantly
decreased the pregnancy rate and increased the early miscarriage rate after IVF/ICSI treatment. The rate
of early miscarriage was higher in the high-ANA-titer individuals after IVF/ICSI treatment. Clinical
pregnancy rate in anti-scl-70- and anti-PM-scl-positive individuals after IVF/ICSI treatment was lower
than that in the ANA-negative individuals. Anti-Rib-p, anti-Jo-1, and anti-dsDNA were found to cause
high risk of early miscarriage in pregnant women.
Conclusion: ANA positivity may not only be the cause of bad outcome during IVF/ICSI treatment, but also
pose as a risk factor for IVF/ICSI treatment.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
In vitro fertilization (IVF) and intracytoplasmic sperm injection
(ICSI) is a technology that has brought hope and possibility of
fertilization to infertile couples. At present, the global incidence of
infertility rate in couples of childbearing age is about 15% and
seems to be increasing day by day. In vitro fertilization-embryo
transfer is a very effective technique that has been evolving over
the past 30 years, but yet, the overall clinical pregnancy rate after
IVF and ICSI treatment still remains 30e40%, implying that multiple
factors could be involved in the mechanism of infertility [1e5].ang District, Beijing 100026,
.
bstetrics & Gynecology. PublishedOver the past few years, there has been a lot of research work
that has clearly demonstrated that the immunological status of the
body is a key factor for a successful pregnancy. The balance of
immunologic tolerance between the mother and the embryo has
been given increasing importance during the process of embryo
implantation and fetal development [6e8]. It is increasingly clear
that the immunological background and environment during
fertilization are very crucial and decisive factors for impregnation.
While investigating the mechanisms underlying the failure of
IVF/ICSI treatment, several researchers have laid focus on autoim-
mune factors such as the antisperm antibody, antiovarian antibody,
antiendometrial antibody, and antiphospholipid antibody. Hence,
over the years, some of these antibodies have become routine tests
for infertility patients in many centers. However, literature has
shown that only a few infertile patients were tested positive for any
of the aforementioned autoantibodies, implying that there must be
other factors and mechanisms underlying the implantation failure.by Elsevier Taiwan LLC. All rights reserved.
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immune factors remains unproven [9,10].
Antinuclear antibodies (ANAs) are a large group of autoanti-
bodies targeting the entire cell including DNAs, RNAs, proteins,
and/or their complexes. ANAs are commonly seen autoantibodies in
autoimmune diseases such as systemic lupus erythematosus and
rheumatoid arthritis. However, it has previously been reported that
while ANA is related to a decline of oocyte quality and an impair-
ment of embryo development, it is also relevant to recurrent
spontaneous abortion, endometriosis, infertility, IVF failure, and
ovarian dysfunction [11e15].
In short, in order to determine the role of ANA in IVF/ICSI
treatment, in this study, we compared the ANA expressions in
infertile women with a fertile control model to see if infertility and
IVF/ICSI treatment failure were related to ANA.
Materials and methods
Patients and grouping
A total of 517 infertile women who were undergoing the ﬁrst
cycle of IVF/ICSI treatment in our faculty were enrolled in the IVF/
ICSI group. By contrast, 186 patients who had given birth to healthy
children without any history of spontaneous abortion over the
recent 2 years were recruited as normal controls. All participants
enrolled in the IVF/ICSI and control groups were duly briefed about
the study, and they signed informed consent forms at the beginning
of the study. They were all recruited at the Beijing Obstetrics and
Gynecology Hospital, Capital Medical University, Beijing, China,
between January 2012 and June 2014. This study was approved by
the local ethics committee.
All patients enrolled in the IVF/ICSI group had to satisfy the
following criteria: (1) age  38 years; (2) undergoing IVF/ICSI for
the ﬁrst time, satisfying all indications for IVF/ICSI treatment with
basal follicle stimulating hormone < 10 mIU/L; and (3) no prior
history of ovarian surgery, chemotherapy, or autoimmune diseases.
By contrast, individuals enrolled for the control group had, in turn,
to satisfy the following criteria: (1) age 38years; (2) given birth to
healthy child over the past 2 years without any prior history of
spontaneous abortion; and (3) no existing pregnancy complication
or autoimmune disease condition.
Detection of ANAs
Serum ANAs were detected by the indirect immunoﬂuorescence
assay (IFA) on a slidewith human epithelial HEp-2 cell line and liver
tissue (monkey) substrate (EUROIMMUN, Luebeck, Germany) in
dilution ratios of 1:100, 1:320, and 1:1000. ANAs would react with
the antigens in the Hep-2 cell substrate, forming antigeneantibody
complexes bound to the cell nucleus. The slides were prepared
following the manufacturer's recommendations and protocol, and
were evaluated under the ﬂuorescence microscope using 20 or
40 objectives. The ANA test was considered positive when the
characteristic ﬂuorescent signal was detected in the tissue or cell,
with a serum dilution ratio of 1:100 (EUROIMMUN). Fluorescence
intensity was interpreted semiquantitatively based on negative and
positive controls.
Further assays were performed following IFA to identify the
autoantibody-targeted extractable nuclear antigens (ENAs) using
the immune blot method (EUROIMMUN). This test identiﬁed the 15
different anti-ENA targets including nRNP, Sm, SS-A, Ro52, SS-B,
Scl-70, PM-Scl, Jo-1, CENP-B, PCNA, dsDNA, nucleosome, histones,
ribosomal P-proteins (Rib-p), and AMA-M2.
All assays were performed and interpreted according to the
manufacturers' protocol.In vitro fertilization-embryo transfer/ICSI protocol
All the infertile patients recruited in the IVF/ICSI group were
stimulated using the traditional gonadotropin-releasing hormone
agonist ﬂare and long luteal-phase protocols, the combinations of
gonadotropin-releasing hormone agonists and gonadotropins.
About 36 hours after the human chorionic gonadotropin (HCG)
injection, the oocytes were picked up. The fertilization program
(conventional IVF or ICSI) was selected based on the semen con-
dition. On the 2nd day or 3rd day after the oocytes were picked up,
morphologic assessment of embryos was carried out under an
inverted microscope before transfer. Embryos graded 1, 2, and 3
were considered available embryos, and those graded 1 and 2 were
considered good-quality or perfect embryos. Pregnancy was diag-
nosed by a positive blood test for b-HCG at 14 days after the embryo
transfer. Clinical pregnancy was diagnosed when the gestational
sac was detected by transvaginal ultrasonography.
Data collection of infertile women
The basic clinical information of infertile women treated with
IVF/ICSI, including their age, body mass index, duration of infer-
tility, and basal level of sex hormone, was collected. Serum levels of
follicle-stimulating hormone, luteinizing hormone, estradiol (E2),
and progesterone were measured. Other parameters that were
recorded were related to the controlled ovarian hyperstimulation
and IVF, including duration of gonadotropin treatment (days); total
dose of gonadotropin; levels of luteinizing hormone, E2, and pro-
gesterone and endometrial thickness on the day of HCG adminis-
tration; number of oocytes picked up; proportion of MII oocytes;
proportion of two-pronuclear embryos; cleavage rate; number of
available embryos; number of transferred embryos; implantation
rate; pregnancy rate; clinical pregnancy rate; and early miscarriage
rate.
Statistical analysis
Statistical analysis was performed using SPSS version 18 statis-
tical software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6.0
software (GraphPad Software Inc., La Jolla, CA, USA). The data were
analyzed using the Chi-squared test (Fisher's exact test was used in
case the sample size was small) and Student t test. A p value of
<0.05 indicated that the difference was statistically signiﬁcant.
Results
Higher level of expression of serum ANAs in the IVF/ICSI group than
in the control group
In the IVF/ICSI group, 39.46% (204/514) patients were found to
be ANA positive by IFA. Moreover, 30.39% (62/204) of the ANA-
positive patients were screened by IFA to have a high ANA titer in
serum. By contrast, in the control group, only 30 cases were tested
to be ANA positive and no high titer of ANAs was found in the
control group. The positive rate of ANA in the serum, the incidences
of ANA positive or high titer of ANA between IVF/ICSI group and
control group were tabulated for proper reference (Figure 1).
Detailed information about the ANA expression in the IVF/ICSI and
control groups is given in Table 1.
In the IVF/ICSI group, anti-ENA test results showed that out of
the 204 patients tested ANA positive, 23 cases were anti-PM-scl
positive, 18 anti-SSA positive, 18 anti-Ro-52 positive, and 13 anti-
histone positive. Twelve patients were tested positive for multiple
anti-ENAs in the serum; nine of them tested double positive for
anti-dsDNA and antihistone, two tested positive for both anti-SSA
Figure 1. ANA expression in the IVF/ICSI and control groups. ANA ¼ antinuclear
antibody; ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro fertilization.
Table 1
Serum ANA expression in the IVF-ET/ICSI and control groups.
IVF/ICSI Control p
Cases 517 186
Age (y) 30.78 ± 3.04 31.03 ± 2.83 0.327
ANA positive 204 (39.45) 30 (16.13) <0.001
Titer of ANAs 1:100 142 (27.46) 30 (16.13) 0.002
1:320 62 (11.99) 0 <0.001
Data are presented as n, n (%), or mean ± standard deviation.
ANA ¼ antinuclear antibody; ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro
fertilization; IVF-ET ¼ in vitro fertilization-embryo transfer.
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scl-70. Immune blot tests, by contrast, failed to identify the anti-
ENAs in the serum of the 96 patients, and this might have been
due to the lower sensitivity of immune blot compared to that of IFA.
Furthermore, there were some antibodies against unusual ENAs in
the samples, which could not be discovered by current methods
and have therefore been placed in the unclassiﬁed subgroup.
Detailed information about the anti-ENA screening in the IVF/ICSI
and control groups has been provided in Table 2.
Impact of ANAs on IVF/ICSI treatment
Comparing the clinical information of the ANA-positive and
-negative patients from the IVF/ICSI group, we found that the total
gonadotropin dose was higher in the ANA-positive patients. We
also discovered that the number of oocytes retrieved from the ANA-Table 2
Anti-ENA expression in the IVF/ICSI and control groups.
IVF/ICSIa Control













Unclassiﬁed ENA 96 21
Anti-ENA ¼ antiextractable nuclear antigen; ICSI ¼ intracytoplasmic sperm injec-
tion; IVF ¼ in vitro fertilization; Rib-p ¼ ribosomal P-proteins.
a Nine anti-dsDNA and antihistone positive, two anti-SSA and anti-Ro-52 positive,
and one anti-PM-scl and anti-scl-70 positive cases were included.positive patients was fewer than that from the ANA-negative pa-
tients after cycles of treatment. As far as the outcome of the
treatment is concerned, we found that implantation rate and clin-
ical pregnancy rate were lower and early miscarriage rate was
higher in the ANA-positive patients than in the ANA-negative pa-
tients (Figure 2). Detailed clinical information of the ANA-positive
and ANA-negative patients from the IVF/ICSI group has been pro-
vided in Table 3.
We further analyzed the effect of the level of ANAs on the
outcome of IVF/ICSI treatment. Our data showed that the E2 level
was higher on the HCG day, and the numbers of retrieved oocytes
and available embryos were more in patients with a low ANA titer
(1:100) than in those with a high ANA titer (1:320). Furthermore,
there was a lower early miscarriage rate in low-ANA-titer (1:100)
patients (Figure 3). Detailed clinical information of patients with
high and low ANA titers from the IVF/ICSI group has been given in
Table 4.
Impact of anti-ENAs on the outcome of the IVF/ICSI group
Out of the 15 anti-ENAs screened in this study, anti-PM-scl and
anti-Scl-70 are most likely to lead to the failure of pregnancy after
IVF/ICSI treatment. Unclassiﬁed anti-ENAs also inﬂuence the
pregnancy rate after IVF/ICSI treatment. However, common anti-
ENAs, such as anti-SSA, anti-Ro-52, and antihistone, did not inﬂu-
ence the pregnancy rate in our cohort (Figure 4). Detailed infor-
mation of the impact of anti-ENAs on the outcome of the IVF/ICSI
treatment group has been provided in Table 5.
Out of the 15 anti-ENAs tested during our study, six did not
hinder pregnancy after IVF/ICSI treatment. Interestingly, during the
analysis of pregnancy rate after IVF/ICSI treatment, we found that
the two pregnant patients tested positive for Rib-p miscarried in
the ﬁrst 3 months of pregnancy. Three of the patients who tested
positive for Jo-1 got pregnant successfully; however, two of them
miscarried early. The same trend was also found in dsDNA-positive
patients. Moreover, unclassiﬁed anti-ENAs positivity was also
found to impact the abortion rate, further underlining the possible
impact of these unclassiﬁed ENAs on the success rate of the treat-
ment (Figure 5). Detailed information about the impact of anti-
ENAs on the outcome of pregnancy has been given in Table 6.
Discussion
In the early stages after fertilization, stability of the nucleus is
the key factor in determining whether the fertilized egg would
successfully develop into an embryo. In the procedure of mitosis,Figure 2. Pregnancy outcome in IVF/ICSI cycles. In the ANAþ group, the implantation
rate (16.09% vs. 27.03%) and clinical pregnancy rate (27.72% vs. 45.03%) decreased
signiﬁcantly, while the early miscarriage rate (21.43% vs. 3.39%) increased in the ANA-
group. *p < 0.001. ANA ¼ antinuclear antibody; ICSI ¼ intracytoplasmic sperm injec-
tion; IVF ¼ in vitro fertilization.
Table 3
Clinical information of patients in the IVF/ICSI group.
ANA expression p
Positive Negative
OPU cycles 204 313
ET cycles 202 262
Age (y) 30.93 ± 3.09 30.69 ± 3.01 0.382
Duration of infertility (y) 4.61 ± 4.76 4.23 ± 3.87 0.315
BMI (kg/m2) 22.82 ± 3.48 22.60 ± 3.83 0.493
bFSH (IU/L) 6.48 ± 1.77 6.40 ± 1.78 0.633
bE2 (ng/mL) 38.46 ± 19.14 41.12 ± 20.74 0.144
bLH (IU/L) 4.86 ± 2.60 4.94 ± 3.28 0.767
Antral follicles 11.05 ± 5.37 11.18 ± 4.64 0.770
Total Gn dose (U) 2487.5 ± 547.03 2303.12 ± 641.60 0.001
E2 on HCG day (ng/mL) 3586.21.75 ± 1953.25 3768.88 ± 1987.89 0.304
Retrieved oocytes 11.33 ± 5.49 12.76 ± 6.97 0.010
ICSI proportion (%) 16.67 (34/204) 17.25 (54/313) 0.862
MII oocyte proportion (%) (ICSI cycle) 85.26 (295/346) 84.72 (671/792) 0.816
2PN proportion (%)
ICSI cycle 79.66 (235/295) 77.65 (521/671) 0.484
IVF cycle 72.43 (1424/1966) 71.76 (2298/3202) 0.606
Cleavage rate (%) 96.93 (1608/1659) 96.99 (2734/2819) 0.912
Available embryos 5.94 ± 2.88 6.16 ± 3.66 0.478
Transferred embryos/cycle 2.00 ± 0.37 2.02 ± 0.58 0.674
High-quality embryo rate overall transferred (%) 97.03 (392/404) 97.73 (517/529) 0.502
Implantation rate (%) 16.09 (65/404) 27.03 (143/529) <0.001
Pregnancy rate (%) 37.62 (76/202) 54.97 (144/262) <0.001
Clinical pregnancy rate (%) 27.72 (56/202) 45.03 (118/262) <0.001
Early miscarriage rate (%) 21.43 (12/56) 3.39 (4/118) <0.001
ANA ¼ antinuclear antibody; bE2 ¼ basal estradiol; bFSH ¼ basal follicle-stimulating hormone; bLH ¼ basal luteinizing hormone; BMI ¼ body mass index; ET ¼ embryo
transfer; E2 ¼ estradiol; Gn ¼ gonadotropin; HCG ¼ human chorionic gonadotropin; ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro fertilization; OPU ¼ oocytes were
picked up; 2PN ¼ two-pronuclear embryos.
Figure 3. Impact of a high ANA titer on IVF/ICSI treatment. High titer of ANA in serum (1: 320) lead to lower level of E2 on HCG Day (A); lower number of retrieved level of oocytes
(B); lower number of available embryos (C) and worse outcome of pregnancy (D). ANA ¼ antinuclear antibody; E2 ¼ estradiol; HCG ¼ human chorionic gonadotropin;
ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro fertilization.
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compositions, including proteins, polysaccharides, and glycopro-
teins, may get exposed at the surface of the cells. In normal situa-
tions, these compositions would not be recognized by the immune
system. However, in an imbalanced immune system, these com-
positions may trigger the activation of autoimmunity. As a group of
autoantibodiesmainly associatedwith the compositions of nucleus,
ANAs have been suspected as an important immune reason of the
failure of implantation [15].As commonly seen autoantibodies, ANAs are linked to several
kinds of autoimmune diseases such as systemic lupus erythe-
matosus and systemic sclerosis. Clinically, there are various
methods for testing serum ANAs; however, IFA has generally been
accepted as the most sensitive method for ANA screening [16]. In
our study, we screened the participants for the presence of ANAs
by IFA and further classiﬁed the targeted antigens to investigate
which autoantibody was responsible for the failure of IVF/ICSI
treatment.
Table 4
Clinical information in the 1:100 and  1:320 ANA titer subgroups.
Titer of ANAs in serum p
1:100 1:320
OPU cycles 142 62
ET cycles 140 62
Age (y) 31.19 ± 3.22 30.32 ± 2.68 0.065
Duration of infertility (y) 4.85 ± 4.36 4.10 ± 5.56 0.303
BMI (kg/m2) 22.86 ± 3.63 22.74 ± 3.12 0.821
bFSH (IU/L) 6.61 ± 1.96 6.20 ± 1.83 0.118
bE2 (ng/mL) 36.02 ± 14.57 41.87 ± 23.76 0.128
bLH (IU/L) 5.02 ± 2.60 4.51 ± 2.56 0.202
Antral follicles 11.23 ± 5.62 10.65 ± 4.77 0.479
Total Gn dose (U) 2495.54.60 ± 638.12 2435.71 ± 459.62 0.086
E2 on HCG day (ng/mL) 3892.08 ± 2128.13 2885.68 ± 1229.33 <0.001
Retrieved oocytes 12.08 ± 5.89 9.63 ± 3.94 0.001
ICSI proportion (%) 17.61 (25/142) 14.52 (9/62) 0.586
MII oocyte proportion (%) (ICSI cycle) 85.45 (235/275) 84.51 (60/71) 0.841
2PN proportion (%)
ICSI cycle 77.45 (182/235) 88.33 (53/60) 0.062
IVF cycle 72.92 (1050/1440) 71.10 (374/526) 0.426
Cleavage rate (%) 96.83 (1193/1232) 97.18 (415/427) 0.714
Available embryos 6.50 ± 2.91 4.66 ± 2.40 <0.001
Transferred embryos/cycle 2.01 ± 0.40 1.97 ± 0.31 0.414
High-quality embryo rate overall transferred (%) 97.16 (274/282) 96.72 (118/122) 0.759
Implantation rate (%) 16.67 (47/282) 14.75 (18/122) 0.631
Pregnancy rate (%) 37.14 (52/140) 38.71 (24/62) 0.832
Clinical pregnancy rate (%) 27.86 (39/140) 27.42 (17/62) 0.949
Early miscarriage rate (%) 12.82 (5/39) 36.84 (7/17) 0.043
ANA ¼ antinuclear antibody; bE2 ¼ basal estradiol; bFSH ¼ basal follicle-stimulating hormone; bLH ¼ basal luteinizing hormone; BMI ¼ body mass index; ET ¼ embryo
transfer; E2 ¼ estradiol; Gn ¼ gonadotropin; HCG ¼ human chorionic gonadotropin; ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro fertilization; OPU ¼ oocytes were
picked up; 2PN ¼ two-pronuclear embryos.
Figure 4. Impact of anti-ENAs on the pregnancy rate post IVF/ICSI treatment. ANA ¼ antinuclear antibody; Anti-ENA ¼ antiextractable nuclear antigen; ICSI ¼ intracytoplasmic
sperm injection; IVF ¼ in vitro fertilization; Rib-p ¼ ribosomal P-proteins.
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tween ANAs and infertility. It has been reported that the expression
rate of ANAs in healthy controls is about 5.9e23.7% and that the
expression rate varies by gender, race, area, and other factors
[17e20]. In our research, the expression rate of ANAs in the control
group was found to be 16.13%, which is coherent with that reported
in the previous literature.
Researchers believe that the presence of ANAs acts as a risk
factor for infertility and can be involved in the mechanism causing
the failure of embryo implantation. Ticconi et al [14] found that
about 50% of spontaneous abortion patients express ANAs, and
researchers further stated that ANAs could be related to infertility,
premature ovarian failure, and embryo transfer failure [11e15]. Due
to the limitations of medical ethics, research work pertaining to the
mechanisms underlying the association between ANAs and infer-
tility has been difﬁcult to pursue. Researchers can investigate only
the link between different clinical phenomena and the expression
of ANAs. The expression rate of ANAs in infertile women varies byresearches and methods used in the research. Kikuchi et al [12]
reported a 28.7% expression rate in patients who underwent IVF/
ICSI treatment, as tested with IFA. In our research, a high ANA
expression rate (39.45%) was found in the IVF/ICSI group, which
was about 2.5 times the ANA expression rate in the control group.
Interestingly, 11.99% (62/517) patients who were undergoing IVF/
ICSI treatment were found to have a high ANA titer (1:320) in
serum, while no patient with a high ANA titer in serumwere found
in the control group.
The presence of a high ANA titer is generally recognized as a
diagnostic factor for autoimmune diseases. However, there still
exist a lot of controversies about autoimmune diseases and infer-
tility. Many researchers believe that autoimmune diseases or
autoimmune phenomena have an effect on the fertility of a patient.
Evidences from the previous literature showed that estrogen could
also trigger autoimmune responses after binding to B lymphocytes,
leading to the generation of high-afﬁnity autoantibodies and
proinﬂammatory cytokines [21]. Hence, the autoantibodies found
Table 5
Impact of anti-ENAs on the pregnancy rate after IVF/ICSI treatment.
Clinical pregnancya Compared with ANA negative
Pregnancy Nonpregnancy Rate (%) p RR OR
ANA negative 118 144 45.03 d d d
ANA positive 56 146 27.72 0.0001 0.6393 0.4681
Unclassiﬁed anti-ENAs 24 70 25.53 0.0009 0.5167 0.4184
Scl-70 0 7 0 0.0193 0.9536 0.0813
PM-Scl 4 19 17.39 0.0141 0.9134 0.2569
nRNP/Sm 3 6 33.33 >0.05
SSA 9 9 50 >0.05
Ro-52 6 12 33.33 >0.05
SSB 0 4 0 >0.05
PCNA 0 1 0 >0.05
Jo-1 3 0 100 >0.05
CENP-B 2 5 28.57 >0.05
dsDNA 3 6 33.33 >0.05
Histones 5 8 38.46 >0.05
Rib-p 2 6 25.00 >0.05
ANA ¼ antinuclear antibody; Anti-ENA ¼ antiextractable nuclear antigen; ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro fertilization; OR ¼ odds ratio; Rib-
p ¼ ribosomal P-proteins; RR ¼ relative risk.
a Nine anti-dsDNA and antihistone positive, two anti-SSA andanti-Ro-52 positive, and one anti-PM-scl and anti-scl-70 positive cases were included.
Figure 5. Impact of anti-ENAs on the outcome of pregnancy after IVF/ICSI treatment. ANA ¼ antinuclear antibody; Anti-ENA ¼ antiextractable nuclear antigen;
ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro fertilization; Rib-p ¼ ribosomal P-proteins.
Table 6
Impact of anti-ENAs on the outcome of pregnancy after IVF/ICSI treatment.
Outcome of pregnancy Compared with ANA negative
Early miscarriage Ongoing pregnancy Rate (%) p RR OR
ANA negative 4 114 3.39 d d d
ANA positive 12 44 21.43 0.0003 2.886 7.773
Unclassiﬁed anti-ENAs 4 20 16.67 0.0280 1.701 5.700
Jo-1 2 1 66.67 0.0061 1.487 57.00
Rib-p 2 0 100 0.0021 1.500 127.2
dsDNA 2 1 66.67 0.0061 1.487 57.00
CENP-B 1 1 50 >0.05
Ro-52 0 6 0 >0.05
SSA 1 8 11.11 >0.05
PM-scl 1 3 25.00 >0.05
histones 1 4 20 >0.05
nRNP/Sm 1 2 33.33 >0.05
ANA ¼ antinuclear antibody; Anti-ENA ¼ antiextractable nuclear antigen; ICSI ¼ intracytoplasmic sperm injection; IVF ¼ in vitro fertilization; OR ¼ odds ratio; Rib-
p ¼ ribosomal P-proteins; RR ¼ relative risk.
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imbalanced immune system, but also account for some kind of
immunologic reproductive system injury. In our study, no patient
was diagnosed with autoimmune diseases. However, the presence
of ANA expression in patients could indicate the possibility of any
sort of immune disorder in them.
Nevertheless,manyANA-positive patients still have the ability to
reproduce,which adds to the controversy regarding the relationshipbetween autoantibodies and infertility. The pregnancy rate in IVF/
ICSI patients might help us reveal the effect of ANA on fertility. Our
results showed statistically signiﬁcant differences in clinical preg-
nancy and miscarriage rates while comparing ANA-positive with
ANA-negative patients in the IVF/ICSI group. In our study, we found
that ANA-positive patients tend to have a lower clinical pregnancy
rate and a higher early miscarriage rate. These results suggest ANAs
are somehow directly or indirectly related to the failure of IVF/ICSI
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to take a higher dosage of gonadotropin while fewer oocytes were
retrieved from them. In recent studies [15,22], ANAs were found to
impair thematuration of oocytes and embryo cell division. Ying et al
[15] revealed that ANAs affected the rates of MII oocyte production,
two-pronuclear embryo production, and division, and the number
of high-quality embryos and transplantable viable embryos, causing
lower pregnancy and implantation rates. Our data also underlined
the impact of ANAs on the outcome of IVF/ICSI treatment.
A high ANA titer did not have a similar effect on the outcome of
IVF/ICSI treatment. The E2 level, retrieved oocytes, and available
embryos of high-ANA-titer patients were lower than those of low-
ANA-titer patients on the HCG day. A higher early miscarriage rate
was found in high-ANA-titer patients. These results indicated that
the level of ANAs in serum did not affect implantation, but had an
adverse effect on oocytes and embryonic development. Zhu et al
[22] reported that an intake of prednisone and aspirin could help
ANA-positive patients improve their IVF/ICSI treatment outcome in
terms of higher numbers of two-pronuclear embryos, high-quality
embryos, and transplantable embryos, and a higher rate of suc-
cessful transplantation. This indicates that a proper treatment tar-
geting the imbalance of immune system could help improve the
outcome of IVF/ICSI treatment in ANA-positive patients.
Few researches have mentioned about the relationship between
anti-ENAs and the outcome of IVF/ICSI treatment. ANAs mainly
work against different compositions of the nucleus, such as DNAs,
RNAs, proteins, or compounds of these substances. It is, therefore,
necessary to ﬁnd out which ENA is related to the failure of IVF/ICSI
treatment. Limited by the current methods of ENA test, we could
only test 15 autoantibody-targeted ENAs. Anti-dsDNA is highly
suspicious of pregnancy failure [23]; although the group number is
small in our research, anti-dsDNA was found to be associated with
an increased possibility of early miscarriage. Interestingly, anti-scl-
70 and anti-PM-scl were found to be highly related to the outcome
of IVF/ICSI treatment. Anti-scl-70 is also called antitopoisomerase I,
and anti-PM-scl is also called antiexosome. In an early report by Li
and Wang [24], mammalian DNA topoisomerase was found to be
essential in early embryogenesis. Anti-scl-70 could impair the
function of topoisomerase, thereby interrupting the process of early
embryogenesis. Furthermore, placenta-derived exosomes were
found to be important downregulators of the immune system in
the endometrium, and antiexosome could further change the im-
mune balance in the endometrium, thus disrupting implantation
[25]. Both anti-scl-70 and anti-PM-scl are linked to an autoimmune
disease, scleroderma [26]. Scleroderma is a rare disease, and a
research in India found a high preterm birth rate, but normal
miscarriage rate, in scleroderma patients [27]. However, that
research mainly included pregnant women, thus being different
from our study. Anti-Rib-p and anti-Jo-1 were also found to in-
crease the possibility of early miscarriage in pregnancy. However,
there is currently no further evidence supporting the negative ef-
fect of these two autoantibodies on pregnancy.
In short, ANA positivity is a risk factor accounting for the failure
of IVF/ICSI treatment. Unlike other autoantibodies commonly
tested before IVF/ICSI treatment, ANAs are commonly seen in
women, and the results of our study pinpoint that one cannot
ignore the inﬂuence of ANAs on the overall outcome of IVF/ICSI
treatment. We also discovered that anti-scl-70 and anti-PM-scl
could be the new therapeutic targets in the IVF/ICSI treatment plan.
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